Statement from U.S. Food and Drug Administration Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research on the FDA’s ongoing Investigation into Valsartan and ARB class Impurities and the Agency’s Steps to Address the Root Causes of the Safety Issues